Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
Christelle BouchartAnne-Laure TrépantMatthieu HeinDirk Van GestelPieter DemetterPublished in: Cancer medicine (2019)
We demonstrated that patients for whom nuclear expression of Olig2 becomes low (<30%) after adjuvant treatments have a significantly shorter time to recurrence and survival reflecting most probably a proneural to mesenchymal transition of the GSCs population. We also highlighted the fact that at initial surgery, high nuclear expression (≥30%) of CCND2, a G1/S regulator specific of GSCs, has a prognostic value and is associated with early mortality (<12 months).
Keyphrases
- stem cells
- poor prognosis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- minimally invasive
- newly diagnosed
- early stage
- binding protein
- bone marrow
- free survival
- coronary artery bypass
- cardiovascular disease
- risk factors
- coronary artery disease
- mesenchymal stem cells
- patient reported outcomes
- percutaneous coronary intervention
- patient reported